By Val Brickates Kennedy Jan 4, 2007 13:24:00 (ET)
BOSTON (MarketWatch) -- Drug stocks moved higher Thursday, while shares of companies whose business focuses on stem cells scored major gains as Democrats assumed control of Congress for the first time since 1995.
The DJ Wilshire Pharmaceutical Index climbed 1% to 2395.92, with the DJ Wilshire Biotechnology Index jumping 2% to 3194.50.
Shares of stem-cell companies rallied, a reflection of hopes that a newly Democratic Congress will make good on its promise to lift certain restrictions on the public funding of embryonic stem-cell research put into place earlier this decade by the Bush administration. Any legislation would likely face a veto from President Bush.
Shares of StemCells Inc. (STEM, Trade ) jumped 13% to $3, while Aastrom Biosciences (ASTM, Trade ) shot up 10% to $1.36. Advance Cell Technology (ACTC, Trade ) also saw its shares get a boost, moving up 9% at 60 cents.
Posted by IMAKEMONEY on :
Profile Get Profile for:
Advanced Cell Technology Inc. 1201 Harbor Bay Parkway Alameda, CA 94501 United States - Map Phone: 510-748-4900 Fax: 510-748-4950 Web Site: http://www.advancedcell.com
DETAILS Index Membership: N/A Sector: Healthcare Industry: Biotechnology Full Time Employees: 37
BUSINESS SUMMARY Advanced Cell Technology, Inc., a biotechnology company, engages in the development and commercialization of human stem cell technology in the fields of regenerative medicine and stem cell therapy in the United States. The company offers RPE cells for the treatment of age-related disease of the eye, including macular degeneration; hemangioblast cells for the treatment of various blood and cardiac disorders; and dermal cells for the treatment of dermal damage, including burns, wound repair, and surgery. It also develops and commercializes products for use in treatment of an array of chronic degenerative diseases and in regenerative repair of acute disease, such as trauma, infarction, and burns. The company, formerly known as A.C.T. Holdings, Inc., was founded in 1994 and is headquartered in Alameda, California.
Key Statistics
COMPANY WEBSITES Home Page
Search Yahoo! for: More on Advanced Cell Technology Inc.
ADVERTISEMENT
View Financials
KEY EXECUTIVES Pay Exercised Mr. William M. Caldwell IV, 58 Chairman, Chief Exec. Officer, Member of Compensation Committee and Member of Nominating & Corp. Governance Committee $ 366.00K $ 0 Dr. Michael D. West Ph.D., 53 Pres, Chief Scientific Officer $ 336.00K $ 0 Mr. Jonathan F. Atzen , 41 Sr. VP, Sec. and Gen. Counsel $ 234.00K $ 0 Dr. Robert P. Lanza M.D., 50 VP of Medical and Scientific Devel. and VP of Medical and Scientific Devel. - Advanced Cell Technology $ 344.00K $ 0 Mr. Ivan Wolkind , 40 Principal Financial Officer, Chief Accounting Officer and VP of Fin. N/A N/A
Dollar amounts are as of 31-Dec-05 and compensation values are for the last fiscal year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of options exercised during the fiscal year.
Posted by IMAKEMONEY on :
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): January 3, 2007
ADVANCED CELL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Delaware
000-50295
87-0656515
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification Number)
1201 Harbor Bay Parkway, Alameda, California 94502
(Address of principal executive offices, including zip code)
(510) 748-4900
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
The Company announced today that it is negotiating an amendment to the Company’s Amortizing Convertible Debentures and Common Stock Purchase Warrants issued under the Securities Purchase Agreement dated as of September 15, 2005 (“2005 Debenture Financing”) and of the Company’s Amortizing Convertible Debentures and Common Stock Purchase Warrants issued under the Securities Purchase Agreement dated as of August 30, 2006 (“2006 Debenture Financing”) between the Company and the holders of such instruments to amend certain terms of these transactions as described below (the “Amendments”). Management expects the Amendments to close within the next several days. Unanimous approval of the holders is required in order for the Amendments to take effect.
The Amendments are expected to have the basic terms described below. All terms are subject to receipt of approval from the remaining uncommitted holders, and may vary materially from those set forth below. No assurance is given that the Company will be able to close the Amendments described herein, or that if the Amendments are closed that the terms and conditions of the Amendments will not differ materially from those described herein.
2005 Debenture Financing Amendment . Subject to receipt of approval of the remaining uncommitted holders, the transaction documents associated with the 2005 Debenture Financing will be amended in the following material respects:
· The conversion price of the debentures will be reset to $0.90.
· The exercise price of the warrants will be reset to $0.95.
· The debentures will be amended to give the Company the right to pay mandatory monthly redemptions in registered shares (or shares of Common Stock eligible for immediate resale under Rule 144) or cash, in the Company’s discretion.
· The Registration Rights Agreement will be amended so as to limit the number of shares of Common Stock required to be registered to an amount not in excess of the limits imposed by the Securities and Exchange Commission’s application of Rule 415 to secondary, resale registration statements, provided that the Company shall register not less than 30% of the Company’s issued and outstanding Common Stock (less shares held by affiliates of the Company) every six months until the registration requirements of the Registration Rights Agreement are satisfied in their entirety, and provided further that the Company shall continue to exercise best efforts to satisfy the registration requirements of the original Registration Rights Agreement as promptly as possible.
· The definition of “Exempt Issuance” will be expanded to include certain additional recipients of options issued under the Company’s approved stock option plans.
2006 Debenture Financing Amendment . Subject to receipt of approval of the remaining uncommitted holders, the transaction documents associated with the 2006 Debenture Financing will be amended in the following respects:
· The commencement of monthly redemptions will be deferred until September 7, 2007.
· The Company will be authorized to withdraw its pending Registration Statement, subject to satisfaction of the provisions of the amended Registration Rights Agreement described immediately below.
· The Registration Rights Agreement will be amended as follows: (a) to require the filing of an initial Registration Statement by the later of the 10 th trading day following the effective date of the Amendment, or January 19, 2007; (b) the number of shares of Common Stock required to be registered is limited to an amount not in excess of the limits imposed by the Securities and Exchange Commission’s application of Rule 415 to secondary, resale registration statements, provided that the Company shall register not less than 30% of the Company’s issued and outstanding Common Stock (less shares held by affiliates of the Company) every six months until the registration requirements of the Registration Rights Agreement are satisfied in their entirety, and provided further that the and provided further that the Company shall continue to exercise best efforts to satisfy the registration requirements of the original Registration Rights Agreement as promptly as possible.
· The Company will covenant to limit cash expenditures to an amount not in excess of $1.3 million per calendar month, subject to certain specified exceptions.
· The definition of “Exempt Issuance” will be expanded to include certain additional recipients of options issued under the Company’s approved stock option plans.
The Company had 39,131,426 shares of Common Stock issued and outstanding as of December 28, 2006.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
ADVANCED CELL TECHNOLOGY, INC.
By:
/s/ William M. Caldwell, IV
William M. Caldwell, IV
Chief Executive Officer
Dated: January 3, 2007
3 ACTC:US Advanced Cell Technology Inc
Industry: Medical-Biomedical/Gene Add Security to your Watch List
01/04 13:39 OTC BB Currency: USD
Price 0.600 Change 0.050 % Change 9.091 Bid 0.590 Ask 0.600 Open 0.550 Volume 758,711 High 0.630 Low 0.550 52-Week High 2.32 (08/24/06) 52-Week Low 0.26 (08/21/06) 1-Yr Return -70.000%
EARNINGS
Earnings Past 12 Months -2.560 Quarter Est. EPS() N.A. Quarter Est. EPS() N.A. Year Est. EPS() N.A. Price/Earnings (Trailing) N.A. Relative P/E N.A. Earnings Growth Rate N.A. Estimated P/E N.A.
FUNDAMENTALS
Shares (Millions) 33.415 Market Cap (Millions) 20.049 Float (Millions) 26.389 Return on Equity N.A. Short Interest N.A. Last Dividend Reported N.A. Dividend Yield (Trailing 12mo.) N.A. Relative Dividend Yield N.A. Composite Indicator Trend Spotter TM Sell
Short Term Indicators 7 Day Average Directional Indicator Sell 10 - 8 Day Moving Average Hilo Channel Sell 20 Day Moving Average vs Price Sell 20 - 50 Day MACD Oscillator Sell 20 Day Bollinger Bands Hold
Short Term Indicators Average: 80% - Sell 20-Day Average Volume - 404570
Medium Term Indicators 40 Day Commodity Channel Index Sell 50 Day Moving Average vs Price Sell 20 - 100 Day MACD Oscillator Sell 50 Day Parabolic Time/Price Sell
Medium Term Indicators Average: 100% - Sell 50-Day Average Volume - 468484
Long Term Indicators 60 Day Commodity Channel Index Sell 100 Day Moving Average vs Price Sell 50 - 100 Day MACD Oscillator Buy
Long Term Indicators Average: 33% - Sell 100-Day Average Volume - 1075131
Overall Average: 80% - Sell
Price Support Pivot Point Resistance
0.5500 0.5133 0.5583 0.6033
Posted by 10of13 on :
Translation? Does this mean that they will be dumping more shares on the market?
Posted by IMAKEMONEY on :
YES AND NO 10, BUT THEY COULD.THIS BROKE RESISTANCE TODAY, NOW WILL IT HOLD AND MOVE UP, SURE MADE ALOT ON THE FIRST RUN. Posted by IMAKEMONEY on :
Advanced Cell Technology's William Caldwell Interviewed By Bloomberg Television
Jan 5, 2007 08:44:23 (ET) PPS .72
ALAMEDA, Calif., Jan 05, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc.'s (ACTC, Trade ) William M. Caldwell, IV, Chief Executive Officer, was interviewed by Bloomberg Television yesterday to comment on the effect the new Congress will have on stem cell funding in its first "100 Hours." As part of an 8-point plan during this time period, Congress has promised to push legislation through that would increase government funding for stem cell research.
Mr. Caldwell spoke of his optimism: "Right now there are bills in front of Congress to expand the lines for stem cell research, but I'm hopeful that this Congress will be cognizant of the fact that this research needs funding. The most important segment of this funding needs to be the translation from the basic science into the development of therapies and products. This void needs to be addressed not only by the government but also by private industry, foundations and consumer groups."
Advanced Cell's commitment to driving therapies to the clinic was recently highlighted in the scientific journal Nature, in a study describing the use of retinal pigment epithelial (RPE) cells derived from the Company's embryonic stem cells, in which vision function was rescued in blind rats. The Company expects to file an investigational new drug application (IND) with the FDA this year for its RPE program. The company expects, further to file INDs for its hemangioblast cell lines for blood and cardiac disorder, and for its dermal cell lines for skin and wound repair, next year.
"We're encouraged with what's happened over the last couple years, not only in California but just recently nationwide with the changes in Congress," said Mr. Caldwell. "Funding stem cell research is a national issue, that should be funded by the National Institute of Health (NIH) and other branches of the government because they have the standards and the policies in place."
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com .
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 Media: Bill Douglass, 212-825-3210
Posted by IMAKEMONEY on :
Drug stocks mixed, stem cell companies gain
By Val Brickates Kennedy Jan 5, 2007 10:37:00 (ET)
BOSTON (MarketWatch) -- Drug stocks were mixed in early action Friday while shares of companies focused on stem cell research rallied for a second day on hopes the newly-Democratic Congress will make good on its promise to increase federal funding for that area of research.
The DJ Wilshire Pharmaceutical Index eased 0.2% to 2392.45 and the DJ Wilshire Biotechnology Index was relatively flat at 3210.56 during a relatively placid morning for the sectors on Wall Street.
Stem cell researchers were up again for the second day, having been on a roll since the Democrats officially took control of Congress on Thursday.
The new Democratic leadership has pledged to reintroduce legislation early this year that would lift certain restrictions on the federal funding of embryonic stem cell research that were put in place by the Bush administration earlier this decade. President Bush has said he would veto the legislation, as he has in the past.
Aastrom Biosciences (ASTM, Trade ) shares hopped 4% to $1.45, while StemCells Inc. (STEM, Trade ) stock rose 6% to $3.29. Shares of Advanced Cell Technology (ACTC, Trade ) jumped 7% to 73 cents a share.
Set Alerts
Create your Personalized SmartAlerts here.
Quotes
To get interactive quotes within this page, download Flash now
Posted by IMAKEMONEY on :
PPS .74 AND ARCA IS FOR SHOW! IMHO
Posted by IMAKEMONEY on :
TOLD YOU ARCA BAILS AND WERE RUNNING!!
Posted by IMAKEMONEY on :
PPS .80 Posted by IMAKEMONEY on :
EOD .79 Posted by IMAKEMONEY on :
PPS 1.15 Posted by Homersbud on :
Well my '07 is sucking ass already. I jumped in at .93, but sold a few minutes later at .89 like a complete moron...I was even debating on buying more around .89-.92 but decided to sell because I thought (shows how dumb I am) it'll tank like everything else I play...What happens after the shake? Explodes to $1.16...
Congrates dude! Can't imagine how much you banked on this...
Posted by IMAKEMONEY on :
THANKS Homersbud, FLIPPING IT, AND STILL SEE LOTS OF UPSIDE,JMO Posted by IMAKEMONEY on :
BACK IN AT .98 Posted by IMAKEMONEY on :
ARCA IS GONE RUNNER!!! PPS 1.02
Posted by IMAKEMONEY on :
EOD 1.04 Posted by Homersbud on :
Damn, nice job dude!
I watched it closely the rest of the afternoon because it just drove me crazy how pathetic my trade was. Nice close. I'm thinking it'll gap, but wtf do I know? lol
Posted by IMAKEMONEY on :
Related Quotes Sym. Price Chg. ACTC Trade News 1.035 0 Advanced Cell Technology CEO Interviewed on CNBC's ''Power Lunch''
Jan 11, 2007 08:33:25 (ET)
ALAMEDA, Calif., Jan 11, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc.'s (ACTC, Trade ) William M. Caldwell, IV, Chief Executive Officer, was interviewed on CNBC Television's "Power Lunch" yesterday to comment on a recent discovery by scientists at Wake Forest University describing a method of deriving stem cells from human amniotic fluid and a bill Congress is expected to take up today to widen the scope of funding for embryonic stem cell research.
Mr. Caldwell commented, "The key for any successful company is focus and we are very driven towards taking therapies, specifically for retinal, blood and cardiac disease into the clinic and ultimately patients. We are excited for Wake Forest and Doctor Atala...(t)hose breakthroughs are exciting and we are going to see more breakthroughs. It's important to remember that the key master cell is the embryonic stem cell and that's the one we are focused on."
Mr. Caldwell continued, "The industry has been starved for many years for lack of capital and we began seeing activity back in 2004 with the voters of California. Now with Congress revisiting the veto that occurred last summer we are going to see a lot more activity in the sector, and we are very excited about it."
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com .
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 Media: Bill Douglass, 212-825-3210
Posted by IMAKEMONEY on :
STRONG LIKE BULL!
Posted by Mortimer on :
Imakemoney, are you long in this?
Anyone know when Stem Cells will come up for discussion in the House? Next week?
Posted by IMAKEMONEY on :
YES I WILL ALWAYS HOLD A FEW THOUSAND SHARES LONG TERM ON THIS PLAY. HOUSE VOTED YES ,BUSH SAYS NO.
Posted by IMAKEMONEY on :
Composite Indicator Trend Spotter TM Buy
Short Term Indicators 7 Day Average Directional Indicator Buy 10 - 8 Day Moving Average Hilo Channel Buy 20 Day Moving Average vs Price Buy 20 - 50 Day MACD Oscillator Sell 20 Day Bollinger Bands Hold
Short Term Indicators Average: 40% - Buy 20-Day Average Volume - 1840095
Medium Term Indicators 40 Day Commodity Channel Index Buy 50 Day Moving Average vs Price Buy 20 - 100 Day MACD Oscillator Sell 50 Day Parabolic Time/Price Buy
Medium Term Indicators Average: 50% - Buy 50-Day Average Volume - 1017646
Long Term Indicators 60 Day Commodity Channel Index Buy 100 Day Moving Average vs Price Buy 50 - 100 Day MACD Oscillator Buy
Long Term Indicators Average: 100% - Buy 100-Day Average Volume - 1370950
Overall Average: 64% - Buy
Price Support Pivot Point Resistance
0.9290 0.8097 0.8997 0.9897
Posted by IMAKEMONEY on :
Advanced Cell Technology Awarded Federal Grant from National Institutes of Health to Accelerate Embryonic Stem Cell Research
Jan 16, 2007 09:33:06 (ET)
ALAMEDA, Calif., Jan 16, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ), applying proprietary human embryonic stem (ES) cell technology to the emerging field of regenerative medicine, has been awarded a research grant from the National Institutes of Health (NIH) in the amount of $204,439 in conjunction with a research project currently underway with one of its academic partners, The Burnham Institute of Medical Research (Burnham Institute).
"This grant is momentous in part because it reflects the changing political climate and the federal government's move toward considerably greater support for research into embryonic stem cell science," said William M. Caldwell, IV, Chairman and Chief Executive Officer of Advanced Cell. "Increases in federal funding can trigger very significant growth in our industry, and grants such as these help companies like Advanced Cell deliver stem cell-based therapies to the bedside."
The grant, titled, "Directed Differentiation of Embryonic Stem Cells using Phage Displayed Ligands," unites Advanced Cell's expertise in embryonic stem cell biology, phage display, phage targeting technology and gene discovery, with Burnham Institute's expertise in developmental biology, cardiac biology, and vascular biology, among others.
"In today's world, medical research is increasingly a collaborative enterprise," said Dr. Michael West, President and Chief Scientific Officer of Advanced Cell. "We are thankful to the NIH and NIDCR for their support and confidence, and we are pleased to be collaborating with the Burnham Institute on this important project."
The NIH grant is issued under a program to foster collaboration between business and academia, and is an important step forward for Advanced Cell proprietary science in the field of embryonic stem cell technology. The award was granted to the company by the National Institute for Dental and Craniofacial Research (NIDCR), a division of the NIH.
The NIH grant will further fund research by Advanced Cell and the Burnham Institute aimed at obtaining specialized cells of therapeutic interest from human embryonic stem cells using NIH-approved stem cell lines. The researchers are investigating the genetic mechanisms and the specific proteins believed to control how basic embryonic stem cells develop and differentiate into specific cells and complex tissues. Such understanding is central to fully harnessing and directing the regenerative powers of stem cells in medical applications, and to the creation and commercialization of stem cell therapies.
Advanced Cell and Burnham Institute researchers are hopeful that their work will have broad application in the stem cell field. "Currently there is a critical need to understand how embryonic stem cells differentiate when cultured in the laboratory and how we can direct the differentiation process to produce cells that are safe and suitable for therapy," said Dr. David Larocca, Associate Director at Advanced Cell and Principal Investigator of the research program.
Advanced Cell and Burnham Institute researchers are focused on cells to treat diseases of the heart, skin, and vascular system.
For example, additional research in collaboration with Burnham Institute is designed to help address the critical unmet medical need for improved skin grafts by identifying new ways to produce human skin equivalents using embryonic stem cells. There is also research being done to develop new treatments for damage to heart muscle. The scientists will seek to develop reagents and processes for purification of cells called "cardiomyocyte precursor cells," and use them to prepare and test cells for cardiac repair.
"There are considerable opportunities in the field of regenerative medicine to use embryonic stem cells to develop therapeutic products to treat diseases where healthy cells may be used to replace those lost to injury or disease," said Dr. Mark Mercola, Ph.D., professor in the Stem Cells and Regeneration at the Burnham Institute. "This grant will allow us to build on our collaboration with Advanced Cell to use phage display as a tool to discover novel molecules for directing stem cells to form useful cell types and tissues."
Advanced Cell and the Burnham Institute recently identified a family of cell-targeting peptides that bind early differentiating human embryonic cells. Researchers are using these cell-targeted peptides to track their developmental fate. This will allow them to identify the precursors of important specialized cells. Once identified by cell-targeting peptides the precursor cells will be isolated and expanded for preclinical and clinical testing.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 Media: Bill Douglass, 212-825-3210 or Financial Communications Trilogy Capital Partners Paul Karon, 800-592-6067 paul*trilogy-capital.com
Posted by IMAKEMONEY on :
Related Quotes Sym. Price Chg. ACTC Trade News 0.99 0.03 Advanced Cell Technology Announces Investor Conference Call to Be Held Friday January 19 to Discuss Key Events and Progress in Stem Cell-Based Therapeutic Programs
Jan 17, 2007 06:30:22 (ET)
ALAMEDA, Calif., Jan 17, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ), applying proprietary human embryonic stem (ES) cell technology to the emerging field of regenerative medicine, will host an investor conference call on Friday, January 19, at 12 noon Eastern, to discuss recent progress and events with respect to the Company's initiatives to develop stem cell-based therapies for a range of diseases and conditions.
During the conference call, William M. Caldwell, IV, Chairman and Chief Executive Officer of Advanced Cell, will provide an overview of Company activities and news, and will address investor questions. Topics he will cover include the Company's recently announced federal research grant from the National Institutes of Health.
Mr. Caldwell will also comment on the impact of the current political climate on the advancement of stem cell based science and technologies. Some states, including California and New Jersey, have enacted legislation to foster stem cell science. Additionally, the newly elected governor of New York State, Eliot Spitzer, recently advocated passage of a $2 billion 10-year bond initiative for research and development, at least half of which would be earmarked for stem cell research.
Interested investors within the United States can access the conference call by calling (800) 553-5275; when prompted tell the operator you would like to connect to the 'Advanced Cell Technology' conference call. International callers can dial (612) 332-1210. An online audio web simulcast of the call will also be accessible at http://www.trilogy-capital.com/tcp/advanced_cell .
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 Media: Bill Douglass, 212-825-3210 or Financial Communications Trilogy Capital Partners Paul Karon, 800-592-6067 paul*trilogy-capital.com
Posted by IMAKEMONEY on :
ARCA IS GONE, WENT TO 1.25 Posted by Fuzzy1018 on :
1.04/1.05
Posted by Fuzzy1018 on :
1.09/1.10
Posted by IMAKEMONEY on :
SmallCap Sentinel: Government Stem Cell Funding Sends Signal to Market
Jan 18, 2007 06:42:45 (ET)
IRVINE, Calif., Jan 18, 2007 (*********wire via COMTEX) -- "For an extended period of time, stem cell equities have busily conducted research under the black cloud of funding limitations," stated SmallCap Sentinel analyst D.R. Clark. "Now, with the political landscape having changed so dramatically, stem cell equities are finding a more welcoming and perhaps brighter path."
"Case in point, Advanced Cell Technology, Inc. (ACTC, Trade ) was awarded a research grant from the National Institutes of Health (NIH) in the amount of $204,439 in conjunction with a research project currently underway with one of its academic partners," Clark noted. "I believe this exemplifies a dramatic change in the government's sentiment toward stem cell research while simultaneously enhancing confidence for Advanced Cell's business plan."
"These types of funding events don't happen for every company that applies," Clark added. "This is a defining moment for Advanced Cell Technology."
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
An informational report titled "Looking at the Political Impact on Stem Cell Research" has been made available free of charge via financial courier StockUpTicks.com at www.SmallCapSentinel.com . The report addresses Advanced Cell Technology, Inc. (ACTC, Trade ), StemCells Inc. (STEM, Trade ), Aastrom Biosciences Inc. (ASTM, Trade ), and Geron Corp. (GERN, Trade ).
To have your company featured in StockUpTicks or SmallCap Sentinel please contact the editors using the information below.
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that affect results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project capabilities, intent, resources, or experience.
Information contained herein is based upon sources believed to be reliable but no representation is made as to accuracy or completeness. This report is neither a solicitation to buy, nor offer to sell securities, but is rather a paid advertisement provided for information purposes only and shouldn't be used as basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid $1,500 by Advanced Cell Technology, Inc. for preparation and distribution of this report and other advertising services. An editor of SmallCap Sentinel currently holds a position in STEM. This constitutes a conflict of interest as to MP's ability to remain objective in communication regarding the subject companies.
SOURCE: SmallCap Sentinel; Advanced Cell Technology, Inc.
Market Pathways and StockUpTicks Shannon Squyres, Editor (949) 955-0107
Posted by seano on :
I'M IN * $1.00
Posted by IMAKEMONEY on :
NICE MOVE IMO seano
Posted by IMAKEMONEY on :
WebAlert: Advanced Cell Technology Conference Call to Start Today at 12 Noon ET
Jan 19, 2007 06:30:10 (ET)
ALAMEDA, Calif., Jan 19, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ), applying proprietary human embryonic stem (ES) cell technology to the emerging field of regenerative medicine, will host a live investor conference call with a simultaneous webcast, today at 12 noon Eastern, to update investors on recent news and events, as well as progress with respect to the Company's initiatives to develop stem cell-based therapies for a range of diseases and conditions.
During the conference call, William M. Caldwell, IV, Chairman and Chief Executive Officer of Advanced Cell Technology, will provide an overview of Company activities and news, will address investor questions and comment on the impact of the current political climate on the advancement of embryonic stem cell science and development. Mr. Caldwell will also discuss the Company's recently announced federal research grant from the National Institutes of Health.
WHO: Advanced Cell Technology
WHAT: Investor Conference Call
WHEN: Today, January 19, 2007, at 12 noon Eastern
HOW: Callers within the United States may dial (800) 553-5275. When prompted, tell the operator that you would like to connect to the Advanced Cell conference call. International callers can dial (612) 332-1210.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California, and Worcester, Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 Media: Bill Douglass, 212-825-3210 or Financial Communications Trilogy Capital Partners Paul Karon, 800-592-6067 paul*trilogy-capital.com
Posted by Spectacles on :
Any ideas on what will happen with this one in the near future?
Posted by IMAKEMONEY on :
UP I HOPE Posted by Spectacles on :
It does'nt look good for today. But,where there's life there's hope. =)
Posted by juice on :
Press Release Source: Advanced Cell Technology, Inc.
Advanced Cell Technology Releases Corporate Video Presentation Highlighting Company's Pioneering Stem Cell Science and Therapeutic Development Programs Monday January 22, 11:02 am ET CEO Outlines Initiatives to Translate Stem Cell-Based Treatments from Laboratory to Clinic to Treat Range of Disease
ALAMEDA, Calif.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (OTCBB:ACTC - News), applying proprietary human embryonic stem (ES) cell technology to the emerging field of regenerative medicine, invites investors to view a new video providing an overview of the Company's unique technologies as well as its overall strategies to develop breakthrough medical therapies for a variety of serious diseases and degenerative conditions. ADVERTISEMENT
In the video, William M. Caldwell IV, Chairman and Chief Executive Officer of Advanced Cell Technology, discusses the Company pioneering innovations relating to the field of human embryonic stem cells (hESc).
Advanced Cell Technology Releases Corporate Video Presentation Highlighting Company's Pioneering Stem Cell Science and Therapeutic Development Programs
Jan 22, 2007 11:02:03 (ET)
ALAMEDA, Calif., Jan 22, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ), applying proprietary human embryonic stem (ES) cell technology to the emerging field of regenerative medicine, invites investors to view a new video providing an overview of the Company's unique technologies as well as its overall strategies to develop breakthrough medical therapies for a variety of serious diseases and degenerative conditions.
In the video, William M. Caldwell IV, Chairman and Chief Executive Officer of Advanced Cell Technology, discusses the Company pioneering innovations relating to the field of human embryonic stem cells (hESc).
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 Media: Bill Douglass, 212-825-3210 or Financial Communications Trilogy Capital Partners Paul Karon, 800-592-6067 paul*trilogy-capital.com
Posted by Spectacles on :
Thanks for the info.
Posted by IMAKEMONEY on :
YEP, LETS HOPE WE MOVE UP ON IT. Posted by IMAKEMONEY on :
Advanced Cell Technology, Inc. Initiation of Coverage and Informational Review Issued by Scimitar Equity Research of ACTC Proprietary Technology and Development Programs
Jan 29, 2007 10:07:00 (ET)
BOSTON, Jan 29, 2007 /PRNewswire via COMTEX/ -- Scimitar Equity Research, Inc. today issued a new Informational Review on Advanced Cell Technology, Inc. (ACTC, Trade ) entitled, "The Road to Commercial Development of New Therapies from Stem Cells."
Advanced Cell Technology (ACT) is a biotechnology company applying human embryonic stem (hES) cell technology in the emerging field of regenerative medicine. ACT is developing novel stem cell-based treatments and cures to target a variety of serious diseases and injuries. ACTC's lead therapeutic development programs include stem cell based treatments for retinal disease such as macular degeneration; diseases of the blood, heart and circulatory system; and dermatological treatments for repair of skin damage from surgery, wounds and burns. ACT has entered development partnerships with leading institutions, and is pursuing additional partnerships with leading biotechnology companies and organizations worldwide. ACTC has announced plans to file in 2007 its first Investigational New Drug Application (IND) with the FDA to treat the eye condition known as macular degeneration.
The analyst research review of ACTC is available on Scimitar's website: www.scimitarequity.com .
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information, please visit: www.advancedcell.com . For investor-specific information and resources, visit
Scimitar Equity Research, Inc. provides sponsored equity research of the healthcare industry for the institutional and investment communities. We certify that all the views expressed in this review, accurately reflect our personal views about Advanced Cell Technology (ACTC, Trade ) and its or their securities. No part of our compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views contained in this review and we will not have any investment banking relationships or personal investment in any sponsored company. Investors are advised that this analysis and review is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. Scimitar was paid for preparing this review. This analysis and review does not have regard to the specific investment objectives, financial situation and the information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate. Any opinions expressed are statements of our own judgment as of the date of publication and are subject to change without notice. Please read all our important disclosures.
CONTACT: Scimitar Equity Research, Inc. Henry W. McCusker Director of Research phone: (617) 559-1080 fax: (617) 559-1083 e-mail: hwm*scimitarequity.com
SOURCE Scimitar Equity Research, Inc.
Henry W. McCusker, Director of Research of Scimitar Equity Research, Inc., +1-617-559-1080, fax: +1-617-559-1083, e-mail: hwm*scimitarequity.com
Advanced Cell Technology Senior Scientist Dr. Robert Lanza Awarded for Outstanding Contributions to Biology by Brown University Biotech Group
Feb 2, 2007 08:33:07 (ET)
ALAMEDA, Calif., Feb 02, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ), applying proprietary human embryonic stem (ES) cell technology to the emerging field of regenerative medicine, has announced that Dr. Robert Lanza, the Company's Vice President of Research and Scientific Development, has been recognized for his groundbreaking research and contributions in stem cell science and biology with a special award from Brown University's Biotechnology Interest Group.
The Brown University biotech group made the award for "Outstanding Contribution in Contemporary Biology" to Dr. Lanza at the organization's 5th Annual Biotech Expo, held February 1, 2007, at Brown's Providence, R.I., campus. Dr. Lanza also delivered a keynote address at the conference.
Dr. Lanza is a noted pioneer in the field of stem cell science, with more than 25 years' experience in the application of stem cells in regenerative medicine. He has published several hundred papers, patents and innovations relating to stem cell science, among them ACTC's Single Cell Blastomere method to derive human embryonic stem cells without harming the donor embryos' potential for life.
"This award helps bring additional notice to the stem cell industry at a point when the field is entering an exciting period of clinical development," said Dr. Lanza. "At ACTC and at institutions around the world, we are focused on the development of powerful new products that have the potential to revolutionize treatment for a growing number of serious diseases and injuries."
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California, and Worcester, Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Trilogy Capital Partners Paul Karon, 800-592-6067 paul*trilogy-capital.com or The Investor Relations Group Investors: James Carbonara, 212-825-3210 Media: Bill Douglass, 212-825-3210
Posted by IMAKEMONEY on :
Advanced Cell Technology Announces Collaboration with the Casey Eye Institute at Oregon Health and Science University
Feb 6, 2007 08:33:21 (ET)
ALAMEDA, Calif., Feb 06, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) today announced that it has entered into a sponsored research agreement with Oregon Health and Science University. The Company is collaborating with Dr. Raymond Lund, Dr. Richard Weleber and Dr. Peter Francis at the Casey Eye Institute to conduct preclinical studies for its Retinal Pigment Epithelium ("RPE") Program. Specifically, the research team is conducting a dosage study utilizing the Company's RPE cells in the Royal College of Surgeons ("RCS") rat model and plans to conduct similar studies in other rodent models of retinal degenerative disease. The Company is also in discussions with the Oregon Health and Science University team in regard to future plans for a Phase I human clinical trial.
Dr. Peter Francis, Assistant Professor of Ophthalmic Genetics and Co-Director of the Oregon Retinal Degeneration Center at the Casey Eye Institute said, "We are very excited to be working with Advanced Cell Technology. This area or research shows great promise for the treatment of a number of blinding conditions."
Mr. William Caldwell, IV, Chairman and CEO of Advanced Cell Technology responded, "We are very excited to be working with the entire team at the Casey Eye Institute. Drs. Lund, Weleber and Francis bring a wealth of experience to our program in the area of retinal degenerative disease. We are also honored to enter into our first collaboration with Oregon Health and Science University, which has clearly distinguished itself as a leader in biomedical research."
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 Media: Bill Douglass, 212-825-3210
Posted by juice on :
cool just buyin at the dips when i can and holdin long. feel real good about this one.... GL you all who are playin actc.
Posted by Mortimer on :
Still in this one myself.
As usual, IMAKEMONEY on top of any breaking news. Thanks man.
Posted by BooDog on :
IMAKE you da MAN!
Posted by IMAKEMONEY on :
LETS JUST HOPE WE CAN RIDE THIS BADBOY TO THE BIG DOLLARS! Posted by juice on :
quote:Originally posted by IMAKEMONEY: LETS JUST HOPE WE CAN RIDE THIS BADBOY TO THE BIG DOLLARS!
im ridin it to the top. great potential with this one, not a fakey pinky GL
Posted by BooDog on :
Press Release Source: Advanced Cell Technology, Inc.
Advanced Cell Technology Acquires Intellectual Property Assets of Infigen, Inc. Thursday February 8, 8:44 am ET Landmark Merger of Embryonic Stem Cell Patent Estates
ALAMEDA, Calif.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (OTCBB: ACTC - News) announced today that it has acquired the intellectual property assets of its former competitor Infigen, Inc. relating to somatic cell nuclear transfer (SCNT), parthenogenesis, and other related technologies. A total of 26 issued patents and numerous pending patent applications were acquired for a combination of cash and shares of common stock. The acquisition provides ACTC with exclusive ownership rights to critical technologies in regenerative medicine and the merger of assets is expected to strengthen ACTC's intellectual property position in the drive towards commercialization of embryonic stem cell and SCNT technology. ADVERTISEMENT
"This tactical acquisition is a part of our long-term plan to become one of the leading companies in the field of regenerative medicine," said William M. Caldwell, IV, Chief Executive Officer of Advanced Cell Technology. "We intend to use these technologies to further our product development and use the exclusive rights under these patents to protect the company and, as appropriate, leverage these patents through licensing transactions with potential strategic partners."
Dennis McCormick, Chairman of Infigen, Inc., commented, "We are pleased to complete this transaction and believe Advanced Cell Technology is one of the preeminent stem cell companies with the ability to commercialize this technology."
Infigen, Inc. heavily invested in its intellectual property portfolio relating to animal cloning and filed some of the earliest and most strategic patents in fundamental steps related to SCNT. One such critical step in SCNT is the activation of oocytes - a process designated "parthenogenetic activation". Egg cells must be activated for SCNT to be successful. In a previous royalty-bearing cross license, ACTC acquired freedom to operate under the Infigen patents in the field of human cell therapy. However, with this acquisition, royalty obligations are removed and ACTC owns the patents exclusively for building its business in regenerative medicine and for use in licensing animal applications.
"We believe the Infigen intellectual property, when merged with our existing proprietary technologies, creates an impressive patent estate. The patents include fundamental technologies useful in the production of any type of cell or tissue matched to the patient through the process of SCNT," said Dr. Michael West, ACTC's President and Chief Scientific Officer. "In addition, in our experience, we believe that this portfolio provides us with a dominant patent position in the production of human embryonic stem cells by parthenogenesis wherein stem cells are made from an egg cell without fertilization or SCNT.
Dr. West continued, "Combining these patents under one roof should simplify the regenerative medicine patent landscape. We will license out the animal applications for use in agriculture and animal science and use the human technologies for our internal programs including applications in the retina, vascular system, and dermatology."
Aquetong Capital Advisors assisted Infigen, Inc. in connection with this transaction.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company visit www.advancedcell.com
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Contact: The Investor Relations Group Investors: James Carbonara, 212-825-3210 Media: Bill Douglass, 212-825-3210
-------------------------------------------------------------------------------- Source: Advanced Cell Technology, Inc.
Posted by BooDog on :
decent long termer with some good prospects. I'm likin it.
Posted by BooDog on :
See also the other recent form 4's Looks like they are buying pretty heavy. Getting ready.
NICE LINKS BOO, THERE A MUST READ !!
Posted by BooDog on :
Thanks IMAKE, it is an indicator that they will at some time take profits but I would think they have had a taste of their potential from where they were just a couple months ago. I would think they would hold and watch this grow. They are looking for sponsorship from some of the big boys. Keeping in mind who is working in this sector in the US one competitor, Neurotech from RI has some major supporters. IMO Advanced Cell is setting themselves up to attract more institutional support also as they gain more visibility. Just getting started IMO. http://thomson.finance.lycos.com/lycos/iwatch/cgi-bin/iw_ticker?ticker=actc Could have some pretty good dips as they gain better footing but long term worth holding a position imo. A couple major pharms pick this up and away she goes.
Just like anything else - it has its piece of pie in the risk area. Watching the form 4’s. Issuing the convertibles… “We elected to make the monthly redemption payments due on March 1, 2007 under certain of our convertible debentures maturing September 14, 2008” makes it look even better eh?
GLTA gonna be interesting watching this one.
Posted by IMAKEMONEY on :
THINK LONG HAUL AND FLIPPING BOO.
Posted by IMAKEMONEY on :
Advanced Cell Technology Names Noted Biotech Industry Executive Dr. Pedro Huertas, as Chief Development Officer to Manage the Clinical Development and Regulatory Approval Process for its Stem Cell-Based Therapeutic Products
Feb 12, 2007 10:18:24 (ET)
ALAMEDA, Calif., Feb 12, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) names Pedro Huertas, MD, PhD, as Chief Development Officer responsible for overseeing the development of the Company's programs to create novel stem cell-based therapeutics, from the pre-clinical stage through clinical development and regulatory approval.
Dr. Huertas, who trained at Harvard-MIT, brings with him extensive experience in medicine, biotechnology start-ups and academic science. Most recently he was Chief Medical Officer at both StemCells, Inc. and Novazyme Pharmaceuticals, Inc. where he managed and directed medical, clinical and regulatory affairs for both companies. At Novazyme, Dr. Huertas positioned and developed the program that was the focus of the company's $185 million acquisition by Genzyme Corporation, which gained FDA approval in 2006 for the first Pompe biotherapeutic agent. At StemCells, Inc. he crafted and filed a successful IND for human neural stem cell transplantation in neuronal ceroid lipofuscinosis.
William M. Caldwell, IV, Chief Executive Officer of Advanced Cell commented, "Dr. Huertas brings a rare combination of scientific excellence and proven business experience in the biotechnology industry to Advanced Cell, and we are fortunate to have him join us at this very important juncture in our Company's development. His expertise will be an invaluable asset to the Company as we accelerate our efforts to develop and commercialize medically valuable stem cell-based therapies and products."
Dr. Huertas said, "Embryonic stem cells are an enormously powerful platform in medical science and offer unparalleled promise in treating some of the cruelest diseases. I look forward to joining Mr. Caldwell, Dr. West, Dr. Lanza and the other members of the talented team, as we work together to develop Advanced Cell's exciting therapeutic programs into the clinic and address the needs of many patients."
Dr. Heurtas has served as a Director of Strategic Development for Genzyme Corporation where he filed a successful biologics license application (BLA) to register Fabrazyme(TM), which achieved worldwide sales of $305 million in 2005 for the treatment of Fabry disease. At Genzyme, Dr. Huertas also conducted a pivotal phase III multi-national trial for Fabry disease and managed its clinical portfolio in related rare genetic diseases.
Most recently, Dr. Huertas served as Chief Strategy and Development Officer at Amicus Therapeutics Inc., where he was recruited to design, implement and manage product development trajectory for pharmacological chaperones. At Amicus, Dr. Huertas was responsible for overall research and development, preclinical and clinical development activities, and also formed Scientific and Medical Advisory Boards. He also established and managed a network of academic, industrial and governmental thought leaders for Amicus.
Dr. Huertas received a Doctor of Medicine degree from Harvard Medical School/ Massachusetts Institute of Technology where he was awarded the Becton Dickinson Research Scholarship and James H. Robinson Memorial Prize in Surgery. He completed his Doctor of Philosophy in Cell and Developmental Biology from Harvard University and also holds a Masters in Business Administration from MIT's Sloan School of Management. As a practicing physician, Dr. Huertas' positions include appointments at McLean Hospital, Massachusetts General Hospital and Harvard University Health Services.
He is a member of the Sloan Fellows Board of Governors, Sloan School of Management at MIT. He is a Charter Member, Advisory Board, of the Division of Health Sciences and Technology Program at Harvard Medical School-MIT and Founding Member, and Member of the Board of Directors of the Biomedical Entrepreneurship Program, at the Sloan School of Management, MIT.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company visit www.advancedcell.com
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 Media: Bill Douglass, 212-825-3210
Posted by IMAKEMONEY on :
Advanced Cell's Michael West, Ph.D., Highlights ACTCellerate Platform, A Means of Accelerating the Differentiation of Cells from Human Embryonic Stem Cells, at 2nd Annual Stem Cell Summit
Feb 13, 2007 08:36:03 (ET)
ALAMEDA, Calif., Feb 13, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc.'s (ACTC, Trade ) Michael West Ph.D., President and Chief Scientific Officer highlighted the Company's ACTCellerate Platform, yesterday, at the 2nd Annual Stem Cell Summit, in San Diego. While the Company's core focus is advancing its therapies related to the eye, vascular system, and skin, the Company believes this platform could augment the potential product applications from what many believe to be the most powerful cell, the human embryonic stem cell.
Human embryonic stem cells (hESC) are the first cells cultured in the laboratory capable of becoming every cell type in the human body. Therefore, the emerging field of regenerative medicine holds great promise for the treatment of many currently untreatable diseases. Despite that potential, researchers have not previously demonstrated efficient means of producing a large array of therapeutically-useful cell types in a pure and scalable form that allows them to be tested for potential human therapeutic use. The Company's proprietary ACTCellerate platform was invented by the Company as a means of accelerating the differentiation of cells from human embryonic stem cells, thereby expanding potential products made from embryonic stem cell technology.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com .
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 or Media: Bill Douglass, 212-825-3210
Posted by IMAKEMONEY on :
GET READY,JMO GREENDAYS AHEAD!
Posted by BooDog on :
chart looks prime for a move IMO. picked up some more first thing this AM... watch out
Posted by juice on :
hmmm .78....well at least i got most of mine from the .60's lol
need a lil' boost....
Posted by BooDog on :
institutional support has gone from 1% to 4% just in the past couple weeks. Not saying we couldn't use a nice dip to add but long term this is lookin better and better. jmho.
GETTEM CHEAP GUYS,JMO, FLIP FLIP FLIP.
Posted by IMAKEMONEY on :
Advanced Cell Applauds $3 Billion Stem Cell Research Program, Proposition 71, Upheld Monday By A California Appeals Court
Feb 28, 2007 10:41:18 (ET)
ALAMEDA, Calif., Feb 28, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) applauds the $3 Billion Stem Cell Research Program, Proposition 71, upheld Monday by a California appeals court. In a unanimous 3-0 ruling judges said Proposition 71 "suffers from no constitutional or other legal infirmity."
William M. Caldwell, IV, Chairman and Chief Executive Officer of Advanced Cell Technology, commented, "California's Proposition 71 may be the world's largest single backer of research in stem cells. We believe a capital infusion could dramatically benefit the stem cell industry, and will fund translational programs, designed to enter the clinic in the near term. We are very proud of Governor Schwarzenegger and California's leadership in helping to maintain a competitive environment for commercial research and development in the stem cell field. We are also fortunate to be headquartered in the great state of California as Advanced Cell works to accelerate its stem cell therapies to the bedside."
Monday, in a public statement, Governor Schwarzenegger said, "Today's ruling is a victory - I always believed the courts would uphold the will of California voters. Stem cell research holds our best promise to find a cure for debilitating illnesses, like Parkinson's disease and diabetes. I'm also proud of California's leadership - we have already awarded the first round grants to researchers to begin work on this potentially life-saving science."
According to the New York Times, Robert N. Klein, chairman of the board overseeing the stem cell program, said the decision was so strong that he thought the California Supreme Court would decline to hear the case if the ruling were appealed and if the Supreme Curt turned away the case, the state could being issuing bonds as soon as 120 days from now.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com .
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 Media: Bill Douglass, 212-825-3210
Posted by BooDog on :
looks like the flippers hopped back in eh?
Posted by juice on :
pieces slowly coming together.... Posted by juice on :
SHES RUNNIN!!! watch out!!! Posted by BooDog on :
Last Trade: 0.86 Trade Time: 3:59PM ET Change: 0.08 (9.62%) Prev Close: 0.78 Open: 0.785 Bid: 0.83 x 2500 Ask: 0.86 x 2500 1y Target Est: 2.51
got some today thats for sure.
Posted by IMAKEMONEY on :
I LIKEEEEEEE IT!! Posted by juice on :
BOOM (again)
Posted by IMAKEMONEY on :
YEP HOD .91 JUST THINK DOLLAR$$$ Posted by BooDog on :
sweet Posted by BooDog on :
Press Release Source: Advanced Cell Technology, Inc.
Advanced Cell Technology's Ability to Rescue Vision in Blind Rats Noted in Scientific American Monday March 5, 5:14 pm ET
ALAMEDA, Calif.--(BUSINESS WIRE)--Advanced Cell Technology, Inc.'s (OTCBB: ACTC - News) ability to rescue vision in blind rats was noted in Scientific American's March 2007 issue as the lead story of its News Scan section. The full text of the article, which notes Advanced Cell's ability to "coax embryonic stem cells to turn into transplantable retinal pigment epithelial (RPE) tissue," is timely as it comes shortly after the company announced its collaboration with the Casey Eye Institute at Oregon Health and Science University (OHSU). ADVERTISEMENT
The article is available at the following link: http://www.sciam.com/article.cfm?chanID=sa006&articleID=C74A4206-E7F2- 99DF-3D2B8FC2C6B5D74C&colID=5 (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists).
Mr. William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology commented, "We are pleased that Scientific American has taken note of Advanced Cell's progress. We are also excited about the many advantages offered by targeting the eye with RPE cells."
One of these advantages is the fact that the eye is immune-privileged, minimizing the use of immune suppressant drugs associated with other areas of the body that by definition reject foreign cells. The eye also requires only a small dosage of cells, reducing the amount necessary to be manufactured, which the company expects to be cost-effective in terms of trials. Another advantage is that the eye is a self-contained site, so the cells gravitate to the RPE layer. Since the site is contained, the cells are less likely to migrate beyond their target application, which could be the case if the site of application were in the blood stream. Additionally, the cells are easier to identify, because of their pigmentation, which is important for purity. Because the cells are easy to identify the risk of injecting foreign, or non-RPE cells into the eye is greatly reduced. Further, age-related diseases of the eye can potentially affect every human being, and ACTC is hopeful that its efforts will help serve a large and growing market.
Mr. Caldwell continued, "Our collaborations at OHSU will be important as we initiate toxicology and pharmacology studies to be managed by our newly appointed Chief Development Officer, Dr. Pedro Huertas. These studies will be important milestones toward our anticipated filing of the company's first Investigational New Drug application (IND) with the FDA."
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company visit www.advancedcell.com
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Contact: The Investor Relations Group Investors: James Carbonara, 212-825-3210 or Media: Bill Douglass, 212-825-3210
-------------------------------------------------------------------------------- Source: Advanced Cell Technology, Inc.
Posted by IMAKEMONEY on :
Advanced Cell Technology's Ability to Rescue Vision in Blind Rats Noted in Scientific American
Mar 5, 2007 17:14:01 (ET)
ALAMEDA, Calif., Mar 05, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc.'s (ACTC, Trade ) ability to rescue vision in blind rats was noted in Scientific American's March 2007 issue as the lead story of its News Scan section. The full text of the article, which notes Advanced Cell's ability to "coax embryonic stem cells to turn into transplantable retinal pigment epithelial (RPE) tissue," is timely as it comes shortly after the company announced its collaboration with the Casey Eye Institute at Oregon Health and Science University (OHSU).
The article is available at the following link: http://www.sciam.com/article.cfm?chanID=sa006&articleID=C74A4206-E7F2- 99DF-3D2B8FC2C6B5D74C&colID=5 (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists).
Mr. William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology commented, "We are pleased that Scientific American has taken note of Advanced Cell's progress. We are also excited about the many advantages offered by targeting the eye with RPE cells."
One of these advantages is the fact that the eye is immune-privileged, minimizing the use of immune suppressant drugs associated with other areas of the body that by definition reject foreign cells. The eye also requires only a small dosage of cells, reducing the amount necessary to be manufactured, which the company expects to be cost-effective in terms of trials. Another advantage is that the eye is a self-contained site, so the cells gravitate to the RPE layer. Since the site is contained, the cells are less likely to migrate beyond their target application, which could be the case if the site of application were in the blood stream. Additionally, the cells are easier to identify, because of their pigmentation, which is important for purity. Because the cells are easy to identify the risk of injecting foreign, or non-RPE cells into the eye is greatly reduced. Further, age-related diseases of the eye can potentially affect every human being, and ACTC is hopeful that its efforts will help serve a large and growing market.
Mr. Caldwell continued, "Our collaborations at OHSU will be important as we initiate toxicology and pharmacology studies to be managed by our newly appointed Chief Development Officer, Dr. Pedro Huertas. These studies will be important milestones toward our anticipated filing of the company's first Investigational New Drug application (IND) with the FDA."
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company visit www.advancedcell.com
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 or Media: Bill Douglass, 212-825-3210
Posted by BooDog on :
beat chya to it this time!! LMAO
Posted by IMAKEMONEY on :
YOU DID! YOU DOG!LOL
Posted by IMAKEMONEY on :
WE JUST MAY GET A BOOST UP ON THIS NEWS! I LIKE THIS PART,Mr. Caldwell continued, "Our collaborations at OHSU will be important as we initiate toxicology and pharmacology studies to be managed by our newly appointed Chief Development Officer, Dr. Pedro Huertas. These studies will be important milestones toward our anticipated filing of the company's first Investigational New Drug application (IND) with the FDA
Posted by BooDog on :
my studies of moneyology might pay off here!
Posted by IMAKEMONEY on :
HERE WE GO BOO!
Posted by IMAKEMONEY on :
Advanced Cell Technology's Ability to Rescue Vision in Blind RatsNoted in Scientific American
Mar 6, 2007 11:35:59 (ET)
ALAMEDA, CA, Mar 06, 2007 (MARKET WIRE via COMTEX) -- Advanced Cell Technology, Inc.'s (ACTC, Trade ) ability to rescue vision in blind rats was noted in Scientific American's March 2007 issue as the lead story of its News Scan section. The full text of the article, which notes Advanced Cell's ability to "coax embryonic stem cells to turn into transplantable retinal pigment epithelial (RPE) tissue," is timely as it comes shortly after the company announced its collaboration with the Casey Eye Institute at Oregon Health and Science University (OHSU).
Mr. William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology, commented, "We are pleased that Scientific American has taken note of Advanced Cell's progress. We are also excited about the many advantages offered by targeting the eye with RPE cells."
One of these advantages is the fact that the eye is immune-privileged, minimizing the use of immune suppressant drugs associated with other areas of the body that by definition reject foreign cells. The eye also requires only a small dosage of cells, reducing the amount necessary to be manufactured, which the company expects to be cost-effective in terms of trials. Another advantage is that the eye is a self-contained site, so the cells gravitate to the RPE layer. Since the site is contained, the cells are less likely to migrate beyond their target application, which could be the case if the site of application were in the blood stream. Additionally, the cells are easier to identify, because of their pigmentation, which is important for purity. Because the cells are easy to identify, the risk of injecting foreign or non-RPE cells into the eye is greatly reduced. Further, age-related diseases of the eye can potentially affect every human being, and ACTC is hopeful that its efforts will help serve a large and growing market.
Mr. Caldwell continued, "Our collaborations at OHSU will be important as we initiate toxicology and pharmacology studies to be managed by our newly appointed Chief Development Officer Dr. Pedro Huertas. These studies will be important milestones toward our anticipated filing of the company's first Investigational New Drug application (IND) with the FDA."
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company visit www.advancedcell.com
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Contact: The Investor Relations Group Investors: James Carbonara 212-825-3210
or
Media: Bill Douglass 212-825-3210
SOURCE: Advanced Cell Technology
Posted by BooDog on :
pick a PR any PR..... give me all your RATS!
Posted by Mortimer on :
Haha, we need to add a new verse to the "three blind mice" song where they get healed by ACTC.
Posted by IMAKEMONEY on :
All-Encompassing Explanation of Nature Puts Biology Into the Equation
Mar 8, 2007 13:02:12 (ET)
WORCESTER, Mass., Mar 08, 2007 (BUSINESS WIRE) -- Advanced Cell Technology's (ACTC, Trade ) Vice-President of Research & Scientific Development, Robert Lanza, M.D.'s, provocative new theory that time and space do not exist as physical realities independent of humans (and animals) has been published in a feature article "A New Theory of the Universe" in the Spring issue of "The American Scholar" (see Cover story http://www.theamericanscholar.org ), one of the nation's leading literary and intellectual publications. Dr. Lanza's article is the first cogent scientific theory that explains in simple, concrete terms, step-by-step, how the universe can be the way it is. Some of the greatest thinkers of our time have had their ideas published in The American Scholar, including Albert Einstein, Stephen Jay Gould, Bertrand Russell, Carl Sagan, John Updike, Robert Frost, Margaret Mead, and Saul Bellow, among others.
Dr. Lanza's new theory presents a shift in worldview with the perspective that life creates the universe instead of the other way around. This theory places biology above the other sciences in an attempt to solve one of nature's biggest puzzles, the theory of everything that other disciplines have been pursuing for the last century. Thousands of articles and books have danced around the desire to toss off the current mechanical worldview that has dominated Western culture for hundreds of years. While some imply that time and space may not in fact exist, Dr. Lanza's article diagrams for the first time, such a universe.
"It's a masterpiece," said Michael Lysaght, Professor of Medical Science at Brown University and Director of Brown's Center for Biomedical Engineering. "It's truly a magnificent essay. Bob Lanza is to be congratulated for a fresh and highly erudite look at the question of how perception and consciousness shape reality and common experience. His monograph combines a deep understanding and broad insight into 20th century physics and modern biological science."
"It is indeed stimulating and brings biology into the whole," said Nobel Laureate E. Donnall Thomas. "Any short statement does not do justice to such a scholarly work. Almost every society of mankind has explained the mystery of our surroundings and being by invoking a god or group of gods. Scientists work to acquire objective answers from the infinity of space or the inner machinery of the atom. Lanza proposes a biocentrist theory which ascribes the answer to the observer rather than the observed. The work is a scholarly consideration of science and philosophy that brings biology into the central role in unifying the whole."
"It is genuinely an exciting piece of work," said Ronald Green Ph.D., a well-known religious studies scholar and Eunice and Julian Cohen Professor for the Study of Ethics and Human Values at Dartmouth College. "The idea that consciousness creates reality has quantum support, and also coheres with some of the things biology and neuroscience are telling us about the structures of our being. Put in a larger context, it exhibits a dramatic new Copernican reversal. Just as we now know that the sun doesn't really move but we do (we are the active agents), this new theory suggests that we are the entities that give meaning to the particular configuration of all possible outcomes we call reality."
Anthony Atala, the W.H. Boyce Professor and Director of the Wake Forest University Institute for Regenerative Medicine says "Robert Lanza, a world renowned scientist who has spanned many fields from drug delivery to stem cells to preventing animal extinction, and clearly one of the most brilliant minds of our times, has done it again. 'A New Theory of the Universe' takes into account all the knowledge we have gained over the last few centuries, and correlates them to our own beings, placing in perspective our biologic limitations that have impeded our understanding of greater truths surrounding our existence and the universe around us. This new theory is certain to revolutionize our concepts of the laws of nature for centuries to come."
"As an astrophysicist," said David Thompson of NASA's Goddard Space Flight Center, "I focus my attention on objects that are very large and very far away, ignoring the whole issue of consciousness as a critical part of the Universe. Reading Robert Lanza's work is a wake-up call to all of us that even on the grandest scale we still depend on our minds to experience reality. Issues of "quantum weirdness" do have a place in the macroscopic world. Time and space do depend on perception. We can go about our daily lives with a better awareness of an underlying biological component, thanks to Dr. Lanza."
"I want to congratulate Dr. Lanza on this massive contribution to scientific thought," said William M. Caldwell, IV, Chairman and CEO of ACTC. "Putting aside the cogent and vibrant writing style, this 'new theory' is an achievement that will stimulate a whole new dimension for scientific debate and discourse. Whether stem cell research or biophysics, ACT scientists are encouraged to think outside of the box. Creative thinking is essential if we are to solve successfully the complex scientific challenges that lie ahead of us."
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company visit www.advancedcell.com
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 or Media: Bill Douglass, 212-825-3210
Posted by BooDog on :
"provocative new theory that time and space do not exist as physical realities independent of humans"
I can't get past this point ~ everything starts shaking ~ space time continuum or something...
lol
Posted by BooDog on :
bump
Press Release Source: Advanced Cell Technology, Inc.
Advanced Cell Technology Executives to Discuss ``The Business of Stem Cells'' and Participate in ``Conversations with Experts'' at The Stem Cell Meeting Hosted by Burrill and Company at UCSF Monday March 12, 9:07 am ET
ALAMEDA, Calif.--(BUSINESS WIRE)--Advanced Cell Technology, Inc.'s (OTCBB: ACTC - News) William M. Caldwell, IV, Chairman and CEO, will discuss "The Business of Stem Cells" at the Stem Cell Meeting, hosted by Burrill and Company at the University of California San Francisco (UCSF), today March 12 2007 at 10:00 AM PT. Also today, Michael West Ph.D., President and Chief Scientific Officer of Advanced Cell will participate as a stem cell expert during the "Conversations with Experts Roundtable Luncheon" at 12:00 PM PT. The conference will be held at the Mission Bay Conference Center at UCSF and will run from March 12-13, 2007.
Posted by IMAKEMONEY on :
I THINK WE SEE A PR IN THE AM, JMO
Posted by IMAKEMONEY on :
I WAS ONE DAY OFF- Advanced Cell Technology hESC lines to be used in CIRM-Funded Study To Test Development of New Therapies For Heart Disease
Mar 20, 2007 08:33:28 (ET)
ALAMEDA, Calif., Mar 20, 2007 (BUSINESS WIRE) -- Preclinical studies using hESCs derived from Advanced Cell Technology, Inc.'s (ACTC, Trade ) proprietary ACTcellerate technology (a means of accelerating the discovery of products from hESC) will be used as part of a study to determine if hESCs are safe and effective in animal models for heart attacks and heart failure.
The studies will be funded under a $2.52 million grant awarded to University of California, San Francisco (UCSF) scientist Randall Lee, M.D, Ph.D., Associate Professor of Medicine, from the California Institute for Regenerative Medicine. The grant is for four years of study. CIRM, the governing body of Proposition 71, manages the $3 billion California initiative.
Michael D. West, Ph.D., President and Chief Scientific Officer of ACTC, said, "We are encouraged that CIRM's funding will potentially speed therapies to the bedside for the 400,000 Americans who die suddenly from new or recurring heart attacks each year. We are pleased to provide the ACTCellerate platform in an effort to provide an alternative to heart transplantation for individuals with severely injured hearts, a treatment that is limited by the availability of donor hearts."
William M. Caldwell, IV, Chairman and CEO of ACTC, added, "We are excited about the implications this current grant has for cardiovascular disease and pleased to be working with academia to help find a solution."
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com .
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the Annual Report on Form 10-KSB for the fiscal year ended December 31, 2006. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
UC Disclaimer
The information stated above was prepared by Advanced Cell Technology, Inc., to report the outcome of their product and reflects solely the opinion of ACT. Nothing in this statement shall be construed to imply any support or endorsement of ACT, or any of its products, by The Regents of the University of California, its officers, agents and employees.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 or Media: Bill Douglass, 212-825-3210
Posted by BooDog on :
You must be part hound IMAKE.
The potential here sure has my attention.
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and Stockholders of Advanced Cell Technology, Inc. Alameda, California
We have audited the accompanying consolidated balance sheet of Advanced Cell Technology, Inc. as of December 31, 2006 and the related consolidated statements of operations, stockholders’ deficit, and cash flows for each of the years in the two-year period ended December 31, 2006. These financial statements are the responsibility of the company’s management. Our responsibility is to express an opinion on these financial statements based on our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Advanced Cell Technology, Inc. as of December 31, 2006 and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2006 in conformity with accounting principles generally accepted in the United States of America.
As discussed in Note 11 to the consolidated financial statements, in 2006 the Company adopted statement of Financial Accounting Standards No. 123 (Revised 2004), Share-Based Payment.
The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has minimal sources of revenue, incurred substantial net losses, has substantial monetary liabilities in excess of monetary assets and accumulated deficits as of December 31, 2006. These matters, among others, raise a substantial doubt about the Company’s ability to continue as a going concern. Management’s plans concerning these matters are described in Note 1. These consolidated financial statements do not included any adjustments relating to the recoverability and classification of recorded assets, or amounts and classification of liabilities that might be necessary in the event the Company cannot continue in existence.
THANKS BOO, JUST WANT TO MAKE MONEY,LOL, I LIKE THIS PICK!!
Posted by IMAKEMONEY on :
Advanced Cell's Michael D. West, Ph.D., to Speak at 3rd Annual Stem Cell Research and Therapeutics Summit on ``Strategies for the Accelerated Development of Therapeutics from hES Cells''
Mar 23, 2007 08:33:10 (ET)
ALAMEDA, Calif., Mar 23, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc.'s (ACTC, Trade ) Michael D. West, Ph.D., President and Chief Scientific Officer, will discuss "Strategies for the Accelerated Development of Therapeutics from hES Cells" at the 3rd Annual Stem Cell Research and Therapeutics Summit hosted by GTCbio today March 23, 2007, at 2:30 PM PT in California. The conference is being held at the San Diego Marriott La Jolla Conference Center and will run from March 22-23, 2007.
In his discussion, Dr. West will discuss the company's ACTCellerate technology and the heart muscle progenitor SK17 that is being studied under a recently funded CIRM grant.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com .
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the Annual Report on Form 10-KSB for the year ended December 31, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 or Media: Bill Douglass, 212-825-3210
Posted by IMAKEMONEY on :
SEE VIDEO ON FRONT PAGE OF YAHOO FINANCE,HMM Posted by BooDog on :
Stem Cell Stocks Set To Soar TheStreet.com TV - Mon, Mar 26 - 4:00pm ET
you talkin about this one? My puter won't load it gotta wait till i get home.
Posted by Jo4321 on :
Advanced Cell's Robert Lanza, M.D. Will Speak on 'Promise: The Future of Stem Cells' Wednesday, March 28, 2007 at 7:30 PM at Quinnipiac University in Hamden, CT, Presented by StemConn 2007
Last update: 3/28/2007 8:30:24 AMALAMEDA, Calif., Mar 28, 2007 (BUSINESS WIRE)
-- Advanced Cell Technology, Inc.'s (ACTC) Robert Lanza, M.D., VP of Research and Scientific Development, will participate in a panel discussion titled, "Promise: The Future of Stem Cell Research," March 28, 2007 at 7:30 PM, at Quinnipiac University in Hamden, CT.
The televised public forum, being presented by StemConn 2007, is for general audiences and focuses on the key issues that surround stem cell research. The panel discussion will be held in the Mancheski Executive Seminar Room, located in the Lender School of Business.
For more information regarding StemConn 2007 including a complete program guide of the two-day event being held March 27-28, 2007, log on to .
About Advanced Cell Technology, Inc. Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit .
Forward-Looking Statements Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the Annual Report on Form 10-KSB for the year ended December 31, 2006. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Advanced Cell's Robert Lanza, M.D. Will Speak on 'Promise: The Future of Stem Cells' Wednesday, March 28, 2007 at 7:30 PM at Quinnipiac University in Hamden, CT, Presented by StemConn 2007
Mar 28, 2007 08:30:24 (ET)
ALAMEDA, Calif., Mar 28, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc.'s (ACTC, Trade ) Robert Lanza, M.D., VP of Research and Scientific Development, will participate in a panel discussion titled, "Promise: The Future of Stem Cell Research," March 28, 2007 at 7:30 PM, at Quinnipiac University in Hamden, CT. The televised public forum, being presented by StemConn 2007, is for general audiences and focuses on the key issues that surround stem cell research. The panel discussion will be held in the Mancheski Executive Seminar Room, located in the Lender School of Business.
For more information regarding StemConn 2007 including a complete program guide of the two-day event being held March 27-28, 2007, log on to http://stemconn.org/program.htm .
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com .
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the Annual Report on Form 10-KSB for the year ended December 31, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 or Media: Bill Douglass, 212-825-3210
Posted by BooDog on :
Fins are out too which could explain the dip. Takes money to make money.
Just having trouble lining these numbers up compared to the form 10 filed earlier (19 Mar)...
"Grant reimbursements for the twelve months ended December 31, 2006 and 2005 were approximately $369,000 and $742,000, respectively."
and...
"Other income/ (expense) for the twelve months ended December 31, 2006 and December 31, 2005 were approximately ($1,037,000) and $1,562,000, respectively"
the other numbers match.
Posted by IMAKEMONEY on :
YES IT DOES BOO.BooDog Member
Member Rated: posted March 28, 2007 10:38 AM -------------------------------------------------------------------------------- Fins are out too which could explain the dip. Takes money to make money.
-------------------------------------------------------------------------------- Posts: 3526 | From: Virginia | Registered: May 2006 | IP: Logged |
Posted by IMAKEMONEY on :
YES YES YES!!
Posted by IMAKEMONEY on :
Advanced Cell Commends Massachusetts Governor Deval Patrick's Decision to Push to Reverse Stem Cell Research Restrictions
Apr 3, 2007 12:17:47 (ET)
ALAMEDA, Calif., Apr 03, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) commends Massachusetts Governor Deval Patrick's decision to reverse stem cell research restrictions imposed by his predecessor, Mitt Romney. Patrick told a roundtable of biotechnology officials at a meeting of the Life Science Council, "I believe that life sciences should be guided by science, not politics." Many in the scientific community contended that Romney's restrictions could have prevented them from using some stem cells. It was also widely asserted that the restrictions undercut a 2005 law that was approved by the state legislature over Romney's veto. Should Patrick successfully reverse the research restrictions, Massachusetts will join a growing number of states that have passed legislation or proposed initiatives to expand funding for embryonic stem cell research. These states include, but are not limited to, California, New York, New Jersey, Connecticut, Florida, and Missouri.
Commenting on the Governor's initiative, Martha Coakley, Attorney General of Massachusetts, recently stated, "I applaud the Governor for taking steps to reverse the regulations put into place by the Romney administration restricting stem cell research in Massachusetts. Through stem cell research, we have the opportunity to cure so many diseases and improve the lives of countless people, not only in Massachusetts, but throughout the country, and in fact, the world."
William M. Caldwell, IV, Chief Executive Officer and Chairman of Advanced Cell Technology, commented, "We could not be more pleased with Governor Patrick's decision to follow-through on his campaign promise to reform the restrictive nature of the stem cell research environment in the state of Massachusetts. We hope this serves as a catalyst for other state governments to move in the same direction, ultimately providing a platform for funding not only for research, but for developmental projects that already exist. The opportunity is at hand for the state to quickly emerge as a national leader in this area of research, by focusing the funding on the translation of the basic science into bedside therapies. Furthermore, we believe that the potential for lifting restrictions on and expanding funding for embryonic stem cell research will help Massachusetts keep biotechnology companies and jobs in the state, where we maintain one of our two principal research and development laboratories."
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com .
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, Joseph Kessler 212-825-3210 or Media: Bill Douglass, 212-825-3210
Posted by BooDog on :
Good support. nice hold.
I can't get my ling for institutional support to wrk. Anyone ahve another link? I was using thomson...
Questions and Comments? Email: support*insidercow.com
Copyright 2003-2007 Insidercow.com. All Rights Reserved.
Posted by BooDog on :
Thanks IMAKE I'm not a member there though. Gotta be another free site that can provide that info. Looks like my wireless keyboard really messed up my last post!
Posted by BooDog on :
ACTC -- Advanced Cell Technology, Inc. Com ($0.001) Search for Dun & Bradstreet reports on this company.
Address: 1201 Harbor Bay Parkway Alameda, CA 94502 USA
Website: http://www.advancedcell.com Phone: (510) 748-4900 Business Description: Not Available Primary State of Incorporation: Delaware Country of Incorporation: USA
Officers: William M. Caldwell IV, CEO
Fiscal Year End: December 31
CIK: 0001140098
Outstanding Shares: 47,232,136 as of 2007-03-12
Estimated Market Cap: 46.287M as of 2007-04-09 (based on Outstanding Shares as of 2007-03-12) Number of Shareholders of Record: 3,000 as of 2007-03-19
just the begining imo. Interview shows that these guys are still at the starting gate but the potential is certainly worth keeping an eye on.
Posted by Lockman on :
Looks like a pretty serious correction. Maybe wait it out for a day or two.IMO
Posted by IMAKEMONEY on :
BUYING IN THE AM! JMO, DO THE DD!
Posted by Lockman on :
quote:Originally posted by IMAKEMONEY: BUYING IN THE AM! JMO, DO THE DD!
Would you consider this a long term hold? Say 2-3 weeks? months?
Posted by BooDog on :
i'm playing this long term. goes up flip out half, goes back down buy more. held this level when i thought for sure it would hit into the .60s. looking for another swing soon. as politics move along stem cell research and the new elections this company (imo) will publicize every angle they can to make a buck. The last interview imo was very honest saying they are still at the starting gate and the potential is pretty good. my call is to play on the momo and take advantage of the flips. - jmho.
Posted by IMAKEMONEY on :
AGREED BOO! Posted by BooDog on :
Last Trade: 0.79 Trade Time: 3:57PM ET Change: 0.00 (0.00%) Prev Close: 0.79 Open: 0.80 Bid: 0.77 x 2500 Ask: 0.79 x 2500 1y Target Est: 2.51
**********: ECMV, IOTN, NURO, TVIA, ACTC, AGSI Have Also Been Removed From Naked Short List Today 2/22/2007... The company, formerly known as A.C.T. Holdings, Inc., was founded in 1994 and is headquartered in Alameda, California. With 33.41 million shares outstanding and 812,538 shares declared short as of January 2007, there is no longer a failure to deliver in shares of ACTC.
http://biz.yahoo.com/ap/070410/congress_stem_cells.html?.v=1 AP Bush Would Veto Stem Cell Research Bill Tuesday April 10, 11:38 am ET By Laurie Kellman, Associated Press Writer White House: Bush Would Veto Bill Subsidizing Stem Cell Research
WASHINGTON (AP) -- President Bush will again veto a bill to subsidize stem cell research using human embryos, but would sign an alternative that permits public funding for studies on embryos incapable of developing into fetuses, the White House said Tuesday.
NEW YORK (AP) -- The Senate is scheduled to take up legislation on Tuesday related to the funding of embryonic stem cell research. The legislation up for debate would lift President Bush's 2001 ban on taxpayer-funded research of embryonic stem cells developed after that time.
[ April 14, 2007, 04:37: Message edited by: BooDog ]
Posted by IMAKEMONEY on :
GONNA GO UP,JMO Posted by IMAKEMONEY on :
Advanced Cell Technology, Inc.'s Q4/06 Analyst Review Issued by Scimitar Equity Research, Inc.
Apr 18, 2007 09:00:00 (ET)
BOSTON, April 18, 2007 /PRNewswire via COMTEX/ -- Scimitar Equity Research, Inc. today issued a Q4/06 Analyst Review on Advanced Cell Technology, Inc. (ACTC, Trade ) entitled, "Translating Stem Cell Development into Therapeutic Outcomes."
Advanced Cell Technology (ACT) is a biotechnology company applying human embryonic stem (hES) cell technology in the emerging field of regenerative medicine. ACT is developing novel stem cell-based treatments and cures to target a variety of serious diseases and injuries. ACTC's lead therapeutic development programs include stem cell based treatments for retinal disease such as macular degeneration; diseases of the blood, heart and circulatory system, and dermatological treatments for repair of skin damage from surgery, wounds and burns. ACT has entered development partnerships with leading institutions, and is pursuing additional partnerships with leading biotechnology companies and organizations worldwide. ACTC has announced plans to file in 2007 its first Investigational New Drug Application (IND) with the FDA treat the eye condition known as macular degeneration.
The analyst research review of ACTC is available on Scimitar's website: www.scimitarequity.com .
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information, please visit: www.advancedcell.com . For investor-specific information and resources, visit
Scimitar Equity Research, Inc. provides sponsored equity research of the healthcare industry for the institutional and investment communities. We certify that all the views expressed in this review, accurately reflect our personal views about Advanced Cell Technology (ACTC, Trade ) and its or their securities. No part of our compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views contained in this review and we will not have any investment banking relationships or personal investment in any sponsored company. Investors are advised that this analysis and review is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. Scimitar was paid for preparing this review. This analysis and review does not have regard to the specific investment objectives, financial situation and the information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate. Any opinions expressed are statements of our own judgment as of the date of publication and are subject to change without notice. Please read all our important disclosures.
CONTACT: Scimitar Equity Research, Inc. Henry W. McCusker Director of Research phone: (617) 559-1080 fax: (617) 559-1083 e-mail: hwm*scimitarequity.com
SOURCE Scimitar Equity Research, Inc.
Henry W. McCusker for Scimitar Equity Research, Inc., Director of Research, +1-617-559-1080, or +1-617-559-1083, or hwm*scimitarequity.com
Eight Companies to Present at EQUITIES 56th Anniversary Spring Conference 2007 Tuesday April 17, 7:39 pm ET
NEW YORK, NY--(MARKET WIRE)--Apr 17, 2007 -- EQUITIES Magazine proudly announces its 56th Anniversary Spring Conference 2007 to be held on Friday, April 20 at the Yale Club in New York City -- the place to be for blossoming companies looking to tell their stories to a sophisticated audience of brokers, fund managers, investment professionals and active retail investors. For over 27 years, EQUITIES has been hosting conferences connecting promising growth companies to investors. This exciting event will be moderated by David Bernard, Publisher and CEO of EQUITIES Magazine, and Victor Webb, President and Managing Director of Marston Webb International. Mr. Webb formerly served as Managing Director of Dow Jones International Marketing Services, and International Director of Dow Jones & Co., Inc.
Of the eight exciting companies presenting, four of these promising public companies are:
-- AeroGrow International (OTC BB:AGWI.OB - News), Boulder, Colorado; a company focusing on indoor aeroponic garden systems. -- Lexam Explorations (CDNX:LEX.V - News), Toronto, Canada; an energy exploration company. The company is advancing the Baca Oil & Gas Project located in Colorado, which is 75% owned by Lexam. -- Advance Cell Technology (OTC BB:ACTC.OB - News), Alameda, California; a biotechnology company engaging in the development and commercialization of human stem cell technology. -- Rocket Info (OTC BB:RKTI.OB - News), Newport Beach, California; a provider of current news and information search solutions. ADVERTISEMENT
About EQUITIES Global Communications, Inc.
EQUITIES Magazine
EQUITIES Global Communications, Inc. is a privately held corporation based in Los Angeles, CA. Covering the most exciting companies in the small and mid-cap markets, EQUITIES Magazine readers include some of the financial community's most savvy and respected investment professionals -- including corporate executives, market makers, traders, fund managers, institutional investors, portfolio managers, stockbrokers, analysts and sophisticated individual investors. In addition, EQUITIES Magazine has developed the most comprehensive investor awareness packages on the market, developing strategic marketing campaigns to help expose promising public companies to the investor marketplace. One of these programs is our EQUITIES Corporate Conferences, currently held six times a year in New York City and once in Europe. EQUITIES is also the publisher of the renowned stock advisory newsletter -- EQUITIES Special Situations, which gained over 21% from 2003 to 2006 according to The Hulbert Financial Digest.
Posted by IMAKEMONEY on :
GOT MY .71s Posted by IMAKEMONEY on :
Advanced Cell Technology's Chairman and CEO, William M. Caldwell, IV, to Present at EQUITIES 56th Anniversary Spring Conference 2007
Apr 20, 2007 08:30:28 (ET)
ALAMEDA, Calif., Apr 20, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc.'s (ACTC, Trade ) Chairman and Chief Executive Officer, William M. Caldwell, IV, has accepted an invitation to present at EQUITIES Magazine's 56th annual Spring Conference at the Yale Club in New York City. Mr. Caldwell's new presentation, scheduled for 11:30AM EST on Friday, April 20, 2007, will include an update on the company's achievements and plans, particularly in light of recent political developments, as general information on trends in human embryonic stem cell research and the emerging field of regenerative medicine.
A live audio web cast of this new presentation can be viewed by visiting the company's web site www.visualwebcaster.com .
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com .
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the Annual Report on Form 10-KSB for the year ended December 31, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara & Joseph Kessler, 212-825-3210 or Media: Bill Douglass, 212-825-3210
Posted by BooDog on :
DOH!!!! you beat me!
Posted by BooDog on :
bb closin in. startin to look better.
Posted by BooDog on :
2007 Milestones Achieved So Far … Hired Chief Development Officer Manufacturing RPE Cells under GMP Compliant conditions Announced RPE Program Collaboration with OHSU for Preclinical Development Acquired Infigen Intellectual Property Portfolio Participated in 2007 CIRM Grants
2007-2008 Milestones To Come … Raise Additional Capital / Achieve Listing on National Exchange Announce Significant Corporate Partnership File IND for RPE Program Complete and Publish Preclinical Work for Hemangioblast and Dermal Programs Gain Approval for Federal Funding of Research Utilizing Blastomere hESC Lines Announce Scientific Breakthrough on Solving Histocompatibility
Posted by IMAKEMONEY on :
NICE WORK BOO!
Posted by BooDog on :
Cheers IMAKE... I thought the conference was just a slideshow so i didn't realize i missed out on the whole audio link 'till paulness mentioned something. Here is the link that works to listen.
Posted by: BooDog In reply to: Paulness who wrote msg# 6264 Date:4/20/2007 8:54:49 PM Post #of 6265
This link poped up when I clicked on www.visualwebcaster.com link from the PR posted on ACTC website. I'll send an e-mail so they can direct everyone to the right place. The link from the PR's from yahoo didn't work - sent me to a calendar.
Posted by MickTrader on :
ACTC and other stem cell comps will move higher as we head toward next election. Once Bush adminst out of office these bills will be pushed through imo.
Posted by IMAKEMONEY on :
"We are increasing our 12 month price target to $2.34 from the $1.50 to 1.75 range based on our Sum-of-The-Parts valuation analysis which is supported by a combination of quantitative valuation methods including a “company comparable” analysis even though ACTC.OB’s are presently at the developmental or pre-clinical stage. We believe shares of ACT offer meaningful upside both in the near and long term. We note that ACTC.OB has constructed a vast patent estate with ownership or exclusive licensing of greater than 30 issued patents and over 280 patent applications in the field of stem cells and regenerative medicine."
gonna take some volume on the plus side to keep it up much less make a run to those levels. keep an eye on the filings imo.
Posted by $Eastwood$ on :
ACTC - UP TO .98 BY THE END OF THE WEEK!
Posted by BooDog on :
long range potential and starting to increase revs keeps me in this. they still have way too much dependence on funding but - when they can stretch their legs on their own look out. of course taking profits on the runs and re-loading on the dips is the way to play along the way.
IMO Posted by BooDog on :
Advanced Cell Technology's General Counsel, Jonathan F. Atzen, Interviewed on Bloomberg Television Friday April 27, 10:21 am ET Comments on Legislative and Legal Environment for Scientific Research on "In Focus"
ALAMEDA, Calif.--(BUSINESS WIRE)--Advanced Cell Technology, Inc.'s (OTCBB: ACTC - News) Senior Vice President and General Counsel, Jonathan F. Atzen, was interviewed by Bloomberg Television yesterday about the legislative and regulatory climate as it affects human embryonic stem cell (hESC) research and development, in a live, five minute interview on the new "in-house counsel" segment of the popular show "in focus." ADVERTISEMENT
Asked about the regulatory hurdles faced by Advanced Cell Technology and other human embryonic stem cell research entities, Mr. Atzen replied, "The difficulty in our business right now from a regulatory perspective revolves around the lack of federal regulation, or leadership, at the federal level. What we're really faced with now is the states filling in on the regulatory side, in terms of funding and in terms of the derivation of these materials."
On the subject of state support of human embryonic stem cell research, particularly in California and Massachusetts, Mr. Atzen said, "Interestingly enough, and probably not by coincidence, we're headquartered in California and have a very important facility in Massachusetts, as well. These are two of the states that are most progressive."
Asked if he sees more states becoming more supportive of hESC research, Mr. Atzen struck an optimistic note. He listed various states which have or are considering pro-stem cell research legislation, such as New York, Connecticut, and Illinois, and reflected, "This is a groundswell. It's a state effort that has taken the place of efforts on the federal level which have not taken effect yet."
Mr. Atzen commented on stem cell patent law, as well, saying, "It's great to be a lawyer in the stem cell industry. Patent law obviously drives our industry... there's a great landscape of IP (intellectual property) out there right now. It's a competitive landscape, and we compete in it aggressively."
Advanced Cell Technology recently announced a collaborative program with the Casey Eye Institute at the Oregon Health & Science University, on its leading indication, its retinal pigment epithelial (RPE) program. The company plans to file an investigational new drug application (IND) with the FDA for this program, which has been demonstrated to rescue vision in blind rats. Moreover, the company expects to file INDs for its hemangioblast cell lines for blood and cardiac disorder, and for its dermal cell lines for skin and wound repair, next year.
A streaming video of the interview will be accessible later today on Advanced Cell's website: http://www.advancedcell.com.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com.
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the annual report on Form 10-KSB for the fiscal year ending December 31, 2007.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Contact: The Investor Relations Group Investors: James Carbonara or Joseph Kessler, 212-825-3210 or Media: Bill Douglass, 212-825-3210 Posted by BooDog on :
.69 maybe get a lil bounce
Posted by IMAKEMONEY on :
NEXT BUY SET AT .64 HOPE WE DONT SEE IT, BUT IM READY!
Posted by IMAKEMONEY on :
FILLED Posted by BooDog on :
WTG m8 we'll see just what she's got eh?
Posted by IMAKEMONEY on :
YEP, I LIKE IT!! BOO Posted by BooDog on :
**********: ACTC, CFPC, CGLD, PLRS Have Also Been Added To Naked Short List Today Tuesday 05/01/2007 9:14 AM ET - M2 **********, www.**********, announced today that these select companies have been added to the NASDAQ, AMEX and NYSE naked short threshold list: Advanced Cell Technology Inc. (OTCBB: ACTC), Coffee Pacifica Inc. (OTCBB: CFPC), Capital Gold Corp. (OTCBB: CGLD), Pluristem Life Systems Inc. (OTCBB: PLRS). For a complete list of companies on the naked short list please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to www.**********.
buy ins.net
Posted by BooDog on :
Advanced Cell Technology and Wisconsin Alumni Research Foundation Announce Commercial License Agreement Wednesday May 2, 5:01 pm ET Agreement Represents Progress Toward Commercial Product Development
ALAMEDA, Calif.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (OTCBB:ACTC - News) today announced an expanded, non-exclusive commercialization agreement with Wisconsin Alumni Research Foundation (WARF). The expanded agreement grants Advanced Cell rights to the commercial use of human embryonic stem cells (hESCs) to develop human therapies, with the exception of neuronal, pancreatic beta cells, and cardiac applications, and enables the marketing of a broad array of research products. This agreement bolsters Advanced Cell's existing patent estate which currently consists of over 380 owned or licensed patents and patent applications worldwide by granting commercial access to an additional 150 important stem cell technology patents and patent applications.
"We believe that the expanded license will afford our company greater flexibility and accelerate the process of bringing ACT's therapeutic programs toward human clinical trials and, ultimately, to commercial adoption and bedside use." said Michael D. West, Ph.D., President and Chief Scientific Officer of Advanced Cell Technology. "The combination of these technologies and the rapidly-growing pipeline coming from our ACTCellerate platform lead us to believe that other clinical applications, in addition to our current target indications, are feasible. These additional therapies include treatment for disorders of the endocrine, craniofacial, muscle, bone, cartilage, liver, kidney, and respiratory systems."
"We have a long history of collaboration with WARF dating back to when our company's president, Dr. West, the founder of Geron Corporation, facilitated the collaboration with Dr. James Thompson at the University of Wisconsin that led to the isolation of the human embryonic stem cell. The addition of these important WARF patents further strengthens ACT's existing broad intellectual property rights in hESC technology," said William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology.
Additional details regarding the commercial license agreement with WARF will be included in a Current Report on Form 8-K to be filed by the Company with the Securities and Exchange Commission.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
Wisconsin Alumni Research Foundation supports world-class research at the University of Wisconsin-Madison by protecting the intellectual property of University faculty, staff and students, and by licensing inventions resulting from their work. Through the licensing efforts, university ideas benefit the public by bringing resources back to the University to continue the cycle of investment, research and invention. Established in 1925, WARF was the first university technology transfer office in the United States.
WHATS YOUR TAKE BOO, I SAY NO BIG DEAL.
Posted by BooDog on :
Looking for a downward trend myself. Keeping my eyes on it though. may turn quickly if they get the right news.
Posted by IMAKEMONEY on :
GREEN!
Posted by IMAKEMONEY on :
PPS .72 MOVING UP!!
Posted by IMAKEMONEY on :
Precursor Cells Generated From Human Embryonic Stem Cells Show Ability to Repair Vascular Damage in Animals BusinessWire - May 07, 2007 1:08 PM ET
Related Quotes Symbol Last Chg ACTC Trade 0.745 +0.105 Real time quote.
Advanced Cell Technology, Inc. (OTCBB: ACTC) reported for the first time that hemangioblast precursor cells derived from human embryonic stem (hES) cells can be used to achieve vascular repair. The research, which appears today online (ahead of print) in the journal Nature Methods, by Advanced Cell Technology (ACT) and its collaborators, describes an efficient method for generating large numbers of bipotential progenitors--known as hemangioblasts--from hES cells that are capable of differentiating into blood vessels, as well as into all blood and immune cell lineages.
"The ability to repair vascular damage using these cells could have a profound impact on a large number of diseases that are major human afflictions," said Robert Lanza, M.D., Vice President of Research & Scientific Development at ACT, and senior author of the study. "Our results suggest the possibility of using nature's early cellular developmental components to restore vascularization and function in patients with vascular disease. An injection of these cells may be able to prevent a patient from having a leg amputated or from dying after a heart attack."
"We have developed for the first time a simple and highly scalable source of human hemangioblasts," stated Shi-Jiang Lu, Ph.D., Director of Differentiation at ACT and first author of the paper. "These proprietary cells represent a new and distinctly different population of cells that can be differentiated into vascular structures and multiple hematopoietic cell types. The elimination of serum and other animal components from the system, as well as the ability to generate an unlimited supply of these cells, will be important for future preclinical and human studies."
When the cells were injected into animals that had damage to their retina due to diabetes or ischemia-reperfusion injury (lack of adequate blood flow) of the retina, the cells homed to the site of injury and showed robust reparative function of the entire damaged vasculature within 24-48 hours. The cells showed a similar regenerative capacity in animal models of both myocardial infarction (50% reduction in mortality rate) and hind limb ischemia, with restoration of blood flow to near normal levels.
"These cells were able to generate functional blood vessels in the presence of severe tissue injury, as well as in chronic disease states," says Maria Grant, M.D., Professor of Pharmacology at the University of Florida, and an author on the paper. "These cells have a robust vascular reparative ability under what is typically considered very adverse growth conditions making them potentially ideal for treatment of diabetic vascular complications where profound tissue compromise exists and healing is typically severely compromised."
"While the cells in this study were tested in animal models, we believe this breakthrough has the potential to benefit many Americans suffering from vascular disease," stated William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology. "ACT is committed to moving this technology from the laboratory into the clinic. We plan on filing an Investigational New Drug Application with the Food and Drug Administration for the first clinical application of these cells by the end of next year."
The researchers of the paper from Advanced Cell Technology collaborated with scientists from the University of Florida, Gainesville, Florida, and the Memorial Sloan-Kettering Cancer Center (MSKCC), New York, New York. The paper's other authors are Qiang Feng of ACT, Sergio Caballero of the University of Florida, and Yu Chen and Malcolm A.S. Moore, DPhil, of MSKCC.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the annual report on Form 10-KSB for the fiscal year ending December 31, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Media FD Robert Stanislaro, 212-850-5657 or Investors The Investor Relations Group Joseph Kessler or James Carbonara 212-825-3210
Posted by $Eastwood$ on :
GO GO GO!!
Posted by IMAKEMONEY on :
FILL THAT GAP AND LETS GO HIGHER!
Posted by IMAKEMONEY on :
NEW HOD .78 Posted by BooDog on :
SWEET
Posted by BooDog on :
ADVANCED CELL TECH (OTC BB:ACTC.OB) Delayed quote data
Last Trade: 0.76 Trade Time: 2:42PM ET Change: 0.12 (18.75%) Prev Close: 0.64 Open: 0.67 Bid: 0.75 x 2500 Ask: 0.77 x 2500 1y Target Est: 2.51
Precursor Cells Generated From Human Embryonic Stem Cells Show Ability to Repair Vascular Damage in Animals Monday May 7, 1:08 pm ET -New, scalable population of hemangioblast cells halves the death rate following heart attack and repairs ischemic limbs and damaged vasculature-
WORCESTER, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (OTCBB: ACTC - News) reported for the first time that hemangioblast precursor cells derived from human embryonic stem (hES) cells can be used to achieve vascular repair. The research, which appears today online (ahead of print) in the journal Nature Methods, by Advanced Cell Technology (ACT) and its collaborators, describes an efficient method for generating large numbers of bipotential progenitors--known as hemangioblasts--from hES cells that are capable of differentiating into blood vessels, as well as into all blood and immune cell lineages.
"The ability to repair vascular damage using these cells could have a profound impact on a large number of diseases that are major human afflictions," said Robert Lanza, M.D., Vice President of Research & Scientific Development at ACT, and senior author of the study. "Our results suggest the possibility of using nature's early cellular developmental components to restore vascularization and function in patients with vascular disease. An injection of these cells may be able to prevent a patient from having a leg amputated or from dying after a heart attack."
"We have developed for the first time a simple and highly scalable source of human hemangioblasts," stated Shi-Jiang Lu, Ph.D., Director of Differentiation at ACT and first author of the paper. "These proprietary cells represent a new and distinctly different population of cells that can be differentiated into vascular structures and multiple hematopoietic cell types. The elimination of serum and other animal components from the system, as well as the ability to generate an unlimited supply of these cells, will be important for future preclinical and human studies."
When the cells were injected into animals that had damage to their retina due to diabetes or ischemia-reperfusion injury (lack of adequate blood flow) of the retina, the cells homed to the site of injury and showed robust reparative function of the entire damaged vasculature within 24-48 hours. The cells showed a similar regenerative capacity in animal models of both myocardial infarction (50% reduction in mortality rate) and hind limb ischemia, with restoration of blood flow to near normal levels.
"These cells were able to generate functional blood vessels in the presence of severe tissue injury, as well as in chronic disease states," says Maria Grant, M.D., Professor of Pharmacology at the University of Florida, and an author on the paper. "These cells have a robust vascular reparative ability under what is typically considered very adverse growth conditions making them potentially ideal for treatment of diabetic vascular complications where profound tissue compromise exists and healing is typically severely compromised."
"While the cells in this study were tested in animal models, we believe this breakthrough has the potential to benefit many Americans suffering from vascular disease," stated William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology. "ACT is committed to moving this technology from the laboratory into the clinic. We plan on filing an Investigational New Drug Application with the Food and Drug Administration for the first clinical application of these cells by the end of next year."
The researchers of the paper from Advanced Cell Technology collaborated with scientists from the University of Florida, Gainesville, Florida, and the Memorial Sloan-Kettering Cancer Center (MSKCC), New York, New York. The paper's other authors are Qiang Feng of ACT, Sergio Caballero of the University of Florida, and Yu Chen and Malcolm A.S. Moore, DPhil, of MSKCC.
Posted by IMAKEMONEY on :
SURE LIKE TO CLOSE OVER .80 Posted by IMAKEMONEY on :
Posted by $Eastwood$ on :
How high is it going to go??
Posted by BooDog on :
bump
give it up shorty!!
Posted by IMAKEMONEY on :
Advanced Cell Technology, Inc. Mid-Quarter Review Issued by Scimitar Equity Research, Inc.
May 8, 2007 09:39:00 (ET)
BOSTON, May 8, 2007 /PRNewswire via COMTEX/ -- Scimitar Equity Research, Inc. today issued aQ4/06 Analyst Review on Advanced Cell Technology, Inc. (ACTC, Trade ) entitled, "'Hemangioblast' Precursor Cells Produced From Human Embryonic Stem Cells Show Remarkable Ability to Repair Vascular Damage in Animals".
Advanced Cell Technology (ACT) is a biotechnology company applying human embryonic stem (hES) cell technology in the emerging field of regenerative medicine. ACT is developing novel stem cell-based treatments and cures to target a variety of serious diseases and injuries. ACTC's lead therapeutic development programs include stem cell based treatments for retinal disease such as macular degeneration; diseases of the blood, heart and circulatory system, and dermatological treatments for repair of skin damage from surgery, wounds and burns. ACT has entered development partnerships with leading institutions, and is pursuing additional partnerships with leading biotechnology companies and organizations worldwide.
The analyst research review of ACTC is available on Scimitar's website: www.scimitarequity.com .
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information, please visit: www.advancedcell.com . For investor-specific information and resources, visit
Scimitar Equity Research, Inc. provides sponsored equity research of the healthcare industry for the institutional and investment communities. We certify that all the views expressed in this review, accurately reflect our personal views about Advanced Cell Technology (ACTC, Trade ) and its or their securities. No part of our compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views contained in this review and we will not have any investment banking relationships or personal investment in any sponsored company. Investors are advised that this analysis and review is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. Scimitar was paid for preparing this review. This analysis and review does not have regard to the specific investment objectives, financial situation and the information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate. Any opinions expressed are statements of our own judgment as of the date of publication and are subject to change without notice. Please read all our important disclosures.
CONTACT: Scimitar Equity Research, Inc. Henry W. McCusker Director of Research phone: (617) 559-1080 fax: (617) 559-1083 e-mail: hwm*scimitarequity.com
SOURCE Scimitar Equity Research, Inc.
Henry W. McCusker, Director of Research for Scimitar Equity Research, Inc., +1-617-559-1080, +1-617-559-1083 (fax), hwm*scimitarequity.com
Advanced Cell Technology's Vice President of Research & Scientific Development to Present at the Life Science Institute's Symposium on Wednesday, May 9, 2007
May 9, 2007 10:26:22 (ET)
ALAMEDA, Calif., May 09, 2007 (BUSINESS WIRE) -- Advanced Cell Technology's (ACTC, Trade ) Vice President of Research and Scientific Development, Dr. Robert Lanza, will be highlighting the company's recent discovery that shows precursor cells, generated from human embryonic stem cells, have the ability to repair vascular damage in animals.
William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology stated, "We consider this to be the most exciting and significant scientific news that our company has ever produced. While the cells in this study were tested in animal models, we believe this breakthrough has the potential to benefit thousands of people suffering from vascular disease ACT is committed to moving this technology from the laboratory into the clinic. Further, we plan on filing an Investigational New Drug Application with the Food and Drug Administration for the first clinical application of these cells by the end of next year."
Dr. Lanza's presentation will take place at The University of Michigan's International Life Sciences Institute in a symposium titled "Frontiers in Stem Cell Biology". Immediately following the symposium, the slides used in Dr. Lanza's presentation may be found on the company's website at www.advancedcell.com .
About The International Life Sciences Institute
Founded in 1978, the International Life Sciences Institute (ILSI) is a nonprofit, worldwide foundation that seeks to improve the well being of the general public through the advancement of science. Its goal is to further the understanding of scientific issues relating to nutrition, food safety, toxicology, risk assessment, and the environment by bringing together scientists from academia, government, and industry.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the annual report on Form 10-KSB for the fiscal year ending December 31, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Media The Investor Relations Group Bill Douglass, 212-825-3210 or Investors The Investor Relations Group Joseph Kessler or James Carbonara 212-825-3210
Posted by IMAKEMONEY on :
Advanced Cell Technology's CEO to Present at Rodman & Renshaw 4th Annual Global Healthcare Conference
May 9, 2007 10:33:15 (ET)
ALAMEDA, Calif., May 09, 2007 (BUSINESS WIRE) -- Advanced Cell Technology (ACTC, Trade ), a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine, will be presenting at Rodman & Renshaw's 4th Annual Global Healthcare Conference in Monte Carlo, Monaco on Monday, May 14th at 5:00 PM local time (11:00 AM EST).
William M. Caldwell, IV, Chairman and CEO, will be providing an update on the Company's developments and business strategy. Further, Mr. Caldwell will be highlighting the company's recent groundbreaking discovery that shows precursor cells, generated from human embryonic stem cells, have the ability to repair vascular damage in animals.
"The ability to repair vascular damage using these cells could have a profound impact on a large number of diseases that are major human afflictions," said Robert Lanza, M.D., Vice President of Research & Scientific Development at ACT, and senior author of the study. "Our results suggest the possibility of using nature's early cellular developmental components to restore vascularization and function in patients with vascular disease. An injection of these cells may be able to prevent a patient from having a leg amputated or from dying after a heart attack."
The Conference will include presentations by over 200 companies, as well as experts from the medical, scientific and investment communities. Mr. Caldwell will be available to meet one-on-one with investors throughout the Conference.
A live audio web cast of this presentation can be accessed via: http://www.wsw.com/webcast/rrshq11/mchm . Further, you can access additional information about Advanced Cell and an audio replay of the presentation on this site for 90 days after the conference.
About Rodman & Renshaw
Rodman & Renshaw, LLC is a privately held, full-service investment bank committed to fostering the long-term success of emerging growth companies through capital raising, strategic advice, insightful research, and the development of institutional support.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the annual report on Form 10-KSB for the fiscal year ending December 31, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Media Bill Douglass, 212-825-3210 or Investors Joseph Kessler or James Carbonara 212-825-3210
Posted by IMAKEMONEY on :
GET READY BOO, ITS GETTING TO BE BUY TIME AGIAN!LOL,JMO Posted by BooDog on :
i'm gonna miss it. already jumped out. lol
Posted by IMAKEMONEY on :
NOW, JMO Posted by IMAKEMONEY on :
Advanced Cell Technology, Inc. Applauds California Supreme Court's Decision Regarding $3 Billion Stem Cell Research Program, Proposition 71
May 17, 2007 09:36:19 (ET)
ALAMEDA, Calif., May 17, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) applauds the $3 Billion Stem Cell Research Program, Proposition 71, upheld yesterday by the California Supreme Court. In a "request denied" ruling, the California Supreme Court declined to review the challenge brought forward by opponents of the measure.
The challenge to Proposition 71 was not upheld by the state appellate court in February of this year. It was then brought before the state Supreme Court, which yesterday declined to consider the petitions.
William M. Caldwell, IV, Chairman and Chief Executive Officer of Advanced Cell Technology, commented, "California voters made their intentions clear three years ago by voting for Proposition 71: they want California to be in the forefront of supporting stem cell research, which has the potential to cure a host of diseases and degenerative conditions. Yesterday, at long last, the final roadblock to implementing the will of the people of the Golden State has been cleared. Yesterday's decision means that California is now on its way to becoming the world's single largest backer of stem cell research. Indeed, the state could start issuing bonds in the very near future."
Mr. Caldwell continued, "Advanced Cell Technology is fortunate to be headquartered in the great state of California as we work to accelerate the transition of our stem cell therapies to the bedside."
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit www.advancedcell.com .
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: Joseph Kessler or James Carbonara, 212-825-3210 or Media: Bill Douglass, 212-825-3210 or Public Affairs: Chad Griffin Consulting, Inc. 310-888-3523
![[Eek!]](eek.gif)
![[Wink]](wink.gif)
![[Big Grin]](biggrin.gif)
![[Cool]](cool.gif)
![[Smile]](smile.gif)
![[Razz]](tongue.gif)
Advanced Cell Technology hESC lines to be used in CIRM-Funded Study To Test Development of New Therapies For Heart Disease